Biogaia

Biogaia's reported carbon emissions

Biogaia, a pharmaceutical preparation manufacturing company headquartered in Sweden, reported approximately 7.26 million kg CO2e in total emissions for the year 2025. This figure encompasses Scope 1, Scope 2, and Scope 3 emissions. For Scope 1, emissions were approximately 90,000 kg CO2e. Scope 2 emissions, using the market-based approach, totalled about 35,000 kg CO2e, while location-based Scope 2 emissions were approximately 260,000 kg CO2e. Significant contributors to their Scope 3 emissions include downstream transportation and distribution at approximately 4.05 million kg CO2e, and purchased goods and services at about 1.71 million kg CO2e. In 2024, Biogaia's total emissions were approximately 3.55 million kg CO2e. Scope 1 emissions stood at about 73,000 kg CO2e, and Scope 2 (market-based) emissions were around 33,000 kg CO2e, with location-based Scope 2 emissions at approximately 208,000 kg CO2e. Scope 3 emissions for 2024 were dominated by downstream transportation and distribution, totalling approximately 4.59 million kg CO2e, and purchased goods and services at roughly 1.65 million kg CO2e. The company has set ambitious climate commitments, including a Science Based Target (SBT) to reduce Scope 1 and 2 GHG emissions by 46% by 2030 from 2019 emission levels. They also commit to measuring and reducing their Scope 3 emissions. Furthermore, Biogaia has set long-term goals to reduce Scope 1 and Scope 2 emissions to near zero. Emissions data is not cascaded from a parent organisation, and their commitments are not part of the Climate Pledge.